BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025)
BioAge Labs' (BIOA) quarterly Non-Current Deffered Revenue came in at $556000.0 in Q3 2025, down 70.77% quarter-over-quarter from $1.9 million in Q2 2025.
Powered by 
Analysis
BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends
BioAge Labs has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $556000.0 for Q3 2025.
- In Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $556000.0; the TTM figure through Sep 2025 stood at $556000.0 (changed N/A YoY), while the FY2024 annual figure was $4.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $556000.0 for Q3 2025 at BioAge Labs, down from $1.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $4.7 million in Q4 2024 to a low of $556000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 556,000.00 |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 4.67 Mn |